TP53 and hypoparathyroidism-retardation-dysmorphism syndrome: Recently, although PARPi and platinum-based chemotherapy significantly improved the survival of breast cancer patients with HRD, whether TP53-specific mutated patients would obtain benefits from PARPi treatment is unknown.